Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges in using circulating miRNAs as cancer biomarkers.
Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Tiberio P, et al. Among authors: appierto v. Biomed Res Int. 2015;2015:731479. doi: 10.1155/2015/731479. Epub 2015 Mar 22. Biomed Res Int. 2015. PMID: 25874226 Free PMC article. Review.
Circulating Biomarkers for Prediction of Treatment Response.
Cappelletti V, Appierto V, Tiberio P, Fina E, Callari M, Daidone MG. Cappelletti V, et al. Among authors: appierto v. J Natl Cancer Inst Monogr. 2015 May;2015(51):60-3. doi: 10.1093/jncimonographs/lgv006. J Natl Cancer Inst Monogr. 2015. PMID: 26063889
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E, Appierto V, Silvestri M, Miceli R, Veneroni S, Folli S, Pruneri G, Vingiani A, Belfiore A, Cappelletti V, Vismara M, Dell'Angelo F, De Cecco L, Bianchi GV, de Braud FG, Daidone MG, Di Cosimo S. Ortolan E, et al. Among authors: appierto v. ESMO Open. 2021 Apr;6(2):100086. doi: 10.1016/j.esmoop.2021.100086. Epub 2021 Mar 17. ESMO Open. 2021. PMID: 33743331 Free PMC article.
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Daidone MG. Di Cosimo S, et al. Among authors: appierto v. Clin Cancer Res. 2019 Jul 1;25(13):3887-3895. doi: 10.1158/1078-0432.CCR-18-2507. Epub 2019 Feb 27. Clin Cancer Res. 2019. PMID: 30814109
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.
Di Cosimo S, Appierto V, Silvestri M, Pruneri G, Vingiani A, Perrone F, Busico A, Folli S, Scaperrotta G, de Braud FG, Bianchi GV, Cavalieri S, Daidone MG, Dugo M. Di Cosimo S, et al. Among authors: appierto v. Cancers (Basel). 2019 Nov 8;11(11):1753. doi: 10.3390/cancers11111753. Cancers (Basel). 2019. PMID: 31717320 Free PMC article.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud FG, Iorio MV, Verderio P, Daidone MG. Di Cosimo S, et al. Among authors: appierto v. Int J Mol Sci. 2020 Feb 18;21(4):1386. doi: 10.3390/ijms21041386. Int J Mol Sci. 2020. PMID: 32085669 Free PMC article. Clinical Trial.
38 results